Aligos Therapeutics

ALGSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$34.283 M

$5.49 +4.77%

Close of 21 Sept 2026

Revenue

$2.19M

#3401 by revenue

Earnings

-$24.2M

Loss-making

Shares outstanding

6,236,828

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#133ElutiaELUT$37.8M
#134Atyr PharmaATYR$36.6M
#135Aligos TherapeuticsALGS$34.3M
#136Genenta Science S.p.A.GNTA$32.6M
#137Quince TherapeuticsQNCX$31.5M

What if Aligos Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$4,848,070

Per share 883,073× higher

Bitcoin $1.72T

$275,408.40

Per share 50,165× higher

Nvidia $5.48T

$877,541.38

Per share 159,844× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for Aligos Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.